Clinical Trial

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 14, 2022 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-09-07.
Status change: Not Yet Recruiting → Recruiting 2022-09-12
Trial Details
NCT Number NCT05536505
Lead Sponsor Guangdong Association of Clinical Trials
Conditions MRD
Enrollment 180 participants
Start Date 2022-09-13
Primary Completion 2025-10-01 (estimated)
Study Completion 2030-10-01 (estimated)
Updated on ClinicalTrials.gov 2022-09-14